CoChat

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

KRAS is the most frequently mutated oncogene in cancer and encodes a key signalling protein in tumours 1,2 . The KRAS(G12C) mutant has a cysteine residue that has been exploited to design covalent inhibitors that have promising preclinical activity 3-5 . Here we optimized a series of inhibitors, using novel binding interactions to markedly enhance their potency and selectivity. Our efforts have led to the discovery of AMG 510, which is, to our knowledge, the first KRAS(G12C) inhibitor in clinical development. In preclinical analyses, treatment with AMG 510 led to the regression of KRAS G12C tumours and improved the anti-tumour efficacy of chemotherapy and targeted agents. In immune-competent mice, treatment with AMG 510 resulted in a pro-inflammatory tumour microenvironment and produced durable cures alone as well as in combination with immune-checkpoint inhibitors. Cured mice rejected the growth of isogenic KRAS G12D tumours, which suggests adaptive immunity against shared antigens. Furthermore, in clinical trials, AMG 510 demonstrated anti-tumour activity in the first dosing cohorts and represents a potentially transformative therapy for patients for whom effective treatments are lacking.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41586-019-1694-1

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

80 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 34 references

Cited by

See all 2,277

Metadata

Authors
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., Lanman, B. A., Werner, J., Rapaport, A. S., San Miguel, T., Ortiz, R., Osgood, T., Sun, J.-R., Zhu, X., McCarter, J. D., Volak, L. P., Houk, B. E., Fakih, M. G., O’Neil, B. H., Price, T. J., Falchook, G. S., Desai, J., Kuo, J., Govindan, R., Hong, D. S., Ouyang, W., Henary, H., Arvedson, T., Cee, V. J., & Lipford, J. R.
Affiliations
  • Amgen (United States) (US)
  • City Of Hope National Medical Center (US)
  • Indiana University School of Medicine (US)
  • Queen Elizabeth Hospital (AU)
  • Peter MacCallum Cancer Centre (AU)
  • Washington University in St. Louis (US)
  • The University of Texas MD Anderson Cancer Center (US)
Corresponding author
  • Canon, Jude
  • Lipford, J. Russell
Venue
Nature
Published
2019-10-30
Volume
575
Issue
7781
Pages
217-223
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2982321167
Cited by
2,277
References
34
Citations by year
2026: 260 · 2025: 324 · 2024: 318 · 2023: 352 · 2022: 361 · 2021: 382 · 2020: 266 · 2019: 10
FWCI
85.07
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Funders
National Institutes of Health (1s10od021832-01)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
KRAS G12C, sotorasib, KRAS inhibitors, covalent inhibitors, antitumor immunity, tumor microenvironment, immune checkpoint inhibitors, adaptive immunity, KRAS G12D, tumor regression, combination therapy
MeSH terms
Animals, Antineoplastic Agents, Drug Synergism, Humans, Immunotherapy, Inflammation, Lung Neoplasms, Phosphorylation, Piperazines, Pyridines, Pyrimidines, Signal Transduction, Proto-Oncogene Proteins p21(ras), Treatment Outcome, Cell Proliferation, Mice, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. https://app.cochat.ai/papers/10.1038/s41586-019-1694-1
The paper
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., Lanman, B. A., Werner, J., Rapaport, A. S., San Miguel, T., Ortiz, R., Osgood, T., Sun, J.-R., Zhu, X., McCarter, J. D., . . . Lipford, J. R. (2019). The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. https://doi.org/10.1038/s41586-019-1694-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.